Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 160

1.

Enhanced immunogenicity of stabilized trimeric soluble influenza hemagglutinin.

Weldon WC, Wang BZ, Martin MP, Koutsonanos DG, Skountzou I, Compans RW.

PLoS One. 2010 Sep 1;5(9). pii: e12466. doi: 10.1371/journal.pone.0012466.

2.

Microneedle vaccination with stabilized recombinant influenza virus hemagglutinin induces improved protective immunity.

Weldon WC, Martin MP, Zarnitsyn V, Wang B, Koutsonanos D, Skountzou I, Prausnitz MR, Compans RW.

Clin Vaccine Immunol. 2011 Apr;18(4):647-54. doi: 10.1128/CVI.00435-10.

3.

A plant-produced H1N1 trimeric hemagglutinin protects mice from a lethal influenza virus challenge.

Shoji Y, Jones RM, Mett V, Chichester JA, Musiychuk K, Sun X, Tumpey TM, Green BJ, Shamloul M, Norikane J, Bi H, Hartman CE, Bottone C, Stewart M, Streatfield SJ, Yusibov V.

Hum Vaccin Immunother. 2013 Mar;9(3):553-60.

4.

A plant-based system for rapid production of influenza vaccine antigens.

Shoji Y, Farrance CE, Bautista J, Bi H, Musiychuk K, Horsey A, Park H, Jaje J, Green BJ, Shamloul M, Sharma S, Chichester JA, Mett V, Yusibov V.

Influenza Other Respir Viruses. 2012 May;6(3):204-10. doi: 10.1111/j.1750-2659.2011.00295.x.

5.

Recombinant soluble, multimeric HA and NA exhibit distinctive types of protection against pandemic swine-origin 2009 A(H1N1) influenza virus infection in ferrets.

Bosch BJ, Bodewes R, de Vries RP, Kreijtz JH, Bartelink W, van Amerongen G, Rimmelzwaan GF, de Haan CA, Osterhaus AD, Rottier PJ.

J Virol. 2010 Oct;84(19):10366-74. doi: 10.1128/JVI.01035-10.

6.

A broadly neutralizing human monoclonal antibody directed against a novel conserved epitope on the influenza virus H3 hemagglutinin globular head.

Benjamin E, Wang W, McAuliffe JM, Palmer-Hill FJ, Kallewaard NL, Chen Z, Suzich JA, Blair WS, Jin H, Zhu Q.

J Virol. 2014 Jun;88(12):6743-50. doi: 10.1128/JVI.03562-13.

7.

Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.

Bright RA, Carter DM, Daniluk S, Toapanta FR, Ahmad A, Gavrilov V, Massare M, Pushko P, Mytle N, Rowe T, Smith G, Ross TM.

Vaccine. 2007 May 10;25(19):3871-8.

PMID:
17337102
9.

Single-dose monomeric HA subunit vaccine generates full protection from influenza challenge.

Mallajosyula JK, Hiatt E, Hume S, Johnson A, Jeevan T, Chikwamba R, Pogue GP, Bratcher B, Haydon H, Webby RJ, McCormick AA.

Hum Vaccin Immunother. 2014;10(3):586-95.

10.

An H1-H3 chimeric influenza virosome confers complete protection against lethal challenge with PR8 (H1N1) and X47 (H3N2) viruses in mice.

Abdoli A, Soleimanjahi H, Tavassoti Kheiri M, Jamali A, Mazaheri V, Abdollahpour Alitappeh M.

Pathog Dis. 2014 Dec;72(3):197-207. doi: 10.1111/2049-632X.12206.

11.

Intranasal immunization of baculovirus displayed hemagglutinin confers complete protection against mouse adapted highly pathogenic H7N7 reassortant influenza virus.

Rajesh Kumar S, Syed Khader SM, Kiener TK, Szyporta M, Kwang J.

PLoS One. 2013 Jun 7;8(6):e63856. doi: 10.1371/journal.pone.0063856.

12.

Development and characterization of a panel of cross-reactive monoclonal antibodies generated using H1N1 influenza virus.

Guo CY, Tang YG, Qi ZL, Liu Y, Zhao XR, Huo XP, Li Y, Feng Q, Zhao PH, Wang X, Li Y, Wang HF, Hu J, Zhang XJ.

Immunobiology. 2015 Aug;220(8):941-6. doi: 10.1016/j.imbio.2015.02.002.

PMID:
25708705
13.

Immunogenicity and safety of H1N1 influenza hemagglutinin protein expressed in a baculovirus system.

Na HN, Kim KH, Song MK, Park HL, Lee EY, Shim SH, Park S, Nam JH.

Microbiol Immunol. 2013 Sep;57(9):660-4. doi: 10.1111/1348-0421.12079.

14.

Yeast expressed recombinant Hemagglutinin protein of novel H1N1 elicits neutralising antibodies in rabbits and mice.

Athmaram TN, Saraswat S, Santhosh SR, Singh AK, Suryanarayana WS, Priya R, Gopalan N, Parida M, Rao PV, Vijayaraghavan R.

Virol J. 2011 Nov 29;8:524. doi: 10.1186/1743-422X-8-524.

15.
16.

Influenza virus-like particles produced by transient expression in Nicotiana benthamiana induce a protective immune response against a lethal viral challenge in mice.

D'Aoust MA, Lavoie PO, Couture MM, Trépanier S, Guay JM, Dargis M, Mongrand S, Landry N, Ward BJ, Vézina LP.

Plant Biotechnol J. 2008 Dec;6(9):930-40. doi: 10.1111/j.1467-7652.2008.00384.x.

17.

Generation and characterization of a cold-adapted attenuated live H3N2 subtype influenza virus vaccine candidate.

An WQ, Yang PH, Duan YQ, Luo DY, Tang C, Jia WH, Xing L, Shi XF, Zhang YJ, Liu XF, Wang XL.

Chin Med J (Engl). 2009 Dec 5;122(23):2880-5.

PMID:
20092795
18.

Neutralizing epitopes of influenza virus hemagglutinin: target for the development of a universal vaccine against H5N1 lineages.

Prabakaran M, He F, Meng T, Madhan S, Yunrui T, Jia Q, Kwang J.

J Virol. 2010 Nov;84(22):11822-30. doi: 10.1128/JVI.00891-10.

19.

Properly folded bacterially expressed H1N1 hemagglutinin globular head and ectodomain vaccines protect ferrets against H1N1 pandemic influenza virus.

Khurana S, Verma S, Verma N, Crevar CJ, Carter DM, Manischewitz J, King LR, Ross TM, Golding H.

PLoS One. 2010 Jul 12;5(7):e11548. doi: 10.1371/journal.pone.0011548.

20.

Protection abilities of influenza B virus DNA vaccines expressing hemagglutinin, neuraminidase, or both in mice.

Fang F, Cai XQ, Chang HY, Wang HD, Yang ZD, Chen Z.

Acta Virol. 2008;52(2):107-12.

PMID:
18564897
Items per page

Supplemental Content

Support Center